Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shaughnessy

Showing results (91-100 of 194) with videos related to

Pageof 20
Sort By:
Echocardiography (Mount Kisco, N.Y.)|September 25, 2001
Reptilian echocardiography: insights into ontogeny and phylogeny?M S Sklansky, D J Levy, W T Elias, et al.
Fertility and Sterility|February 6, 1999
Assessment of interlaboratory and intralaboratory sperm morphology readings with the use of a Hamilton Thorne Research integrated visual optical system semen analyzerK Coetzee, T F Kruger, C J Lombard, et al.
Cancer|October 15, 2010
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsSarah Waheed, John D Shaughnessy, Frits van Rhee, et al.
Leukemia|January 18, 2008
Suppression of abnormal karyotype predicts superior survival in multiple myelomaV Arzoumanian, A Hoering, J Sawyer, et al.
Blood|February 4, 2010
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBijay Nair, Frits van Rhee, John D Shaughnessy, et al.
Cell|November 15, 1996
Absence epilepsy in tottering mutant mice is associated with calcium channel defectsC F Fletcher, C M Lutz, T N O'Sullivan, et al.
Cancer|May 13, 2008
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie, Elias Anaissie, Jeffrey Haessler, et al.
Blood Advances|September 27, 2023
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMSWancheng Guo, Anne Zhan, David E Mery, et al.
Blood|November 11, 2011
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplificationOwen W Stephens, Qing Zhang, Pingping Qu, et al.
Ejhaem|May 19, 2023
Variability of definition of high-risk multiple myeloma across phase III clinical trialsFaris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, et al.
Pageof 20

Showing results (91-100 of 194) with videos related to

Sort By:
Pageof 20
Echocardiography (Mount Kisco, N.Y.)|September 25, 2001
Reptilian echocardiography: insights into ontogeny and phylogeny?M S Sklansky, D J Levy, W T Elias, et al.
Fertility and Sterility|February 6, 1999
Assessment of interlaboratory and intralaboratory sperm morphology readings with the use of a Hamilton Thorne Research integrated visual optical system semen analyzerK Coetzee, T F Kruger, C J Lombard, et al.
Cancer|October 15, 2010
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsSarah Waheed, John D Shaughnessy, Frits van Rhee, et al.
Leukemia|January 18, 2008
Suppression of abnormal karyotype predicts superior survival in multiple myelomaV Arzoumanian, A Hoering, J Sawyer, et al.
Blood|February 4, 2010
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBijay Nair, Frits van Rhee, John D Shaughnessy, et al.
Cell|November 15, 1996
Absence epilepsy in tottering mutant mice is associated with calcium channel defectsC F Fletcher, C M Lutz, T N O'Sullivan, et al.
Cancer|May 13, 2008
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie, Elias Anaissie, Jeffrey Haessler, et al.
Blood Advances|September 27, 2023
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMSWancheng Guo, Anne Zhan, David E Mery, et al.
Blood|November 11, 2011
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplificationOwen W Stephens, Qing Zhang, Pingping Qu, et al.
Ejhaem|May 19, 2023
Variability of definition of high-risk multiple myeloma across phase III clinical trialsFaris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, et al.
Pageof 20